Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Cannabis Bioscience International Holdings (CBIH) EBITDA (2022 - 2026)

Cannabis Bioscience International Holdings filings provide 5 years of EBITDA readings, the most recent being -$93259.0 for Q1 2026.

  • On a quarterly basis, EBITDA rose 27.84% to -$93259.0 in Q1 2026 year-over-year; TTM through Feb 2026 was -$398820.0, a 26.17% decrease, with the full-year FY2025 number at -$421365.0, up 13.32% from a year prior.
  • EBITDA reached -$93259.0 in Q1 2026 per CBIH's latest filing, up from -$95877.0 in the prior quarter.
  • The five-year high for EBITDA was -$29634.0 in Q2 2024, with the low at -$284866.0 in Q1 2023.
  • A 5-year average of -$134968.4 and a median of -$113419.0 in 2024 define the central range for EBITDA.
  • Year-over-year, EBITDA surged 89.22% in 2024 and then crashed 355.22% in 2025.
  • Year by year, EBITDA stood at -$183608.0 in 2022, then skyrocketed by 48.53% to -$94512.0 in 2023, then soared by 36.91% to -$59627.0 in 2024, then plummeted by 60.79% to -$95877.0 in 2025, then grew by 2.73% to -$93259.0 in 2026.
  • Per Business Quant, the three most recent readings for CBIH's EBITDA are -$93259.0 (Q1 2026), -$95877.0 (Q4 2025), and -$74784.0 (Q3 2025).